Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
Department of Transfusion Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
J Clin Apher. 2024 Jun;39(3):e22130. doi: 10.1002/jca.22130.
This study aimed to evaluate the safety and efficacy of therapeutic plasma exchange (TPE) in pediatric acute liver failure (PALF).
All children aged 2-18 years with PALF were included. The intervention cohort included a subset of PALF patients undergoing complete three sessions of TPE, whereas the matching controls were derived by propensity score matching from the patient cohort who did not receive any TPE. Propensity matching was performed based on the international normalized ratio (INR), grade of hepatic encephalopathy (HE), age, bilirubin, and ammonia levels. The primary outcome measure was native liver survival (NLS) in the two arms on day 28.
Of the total cohort of 403 patients with PALF, 65 patients who received TPE and 65 propensity-matched controls were included in analysis. The 2 groups were well balanced with comparable baseline parameters. On day 4, patients in the TPE group had significantly lower INR (P = 0.001), lower bilirubin (P = 0.008), and higher mean arterial pressure (MAP) (P = 0.033) than controls. The NLS was 46.15% in the TPE arm and 26.15% in the control arm. The overall survival (OS) was 50.8% in the TPE arm and 35.4% in the control arm. Kaplan-Meier survival analysis showed a significantly higher NLS in patients receiving TPE than controls (P = 0.001). On subgroup analysis, NLS benefit was predominantly seen in hepatitis A-related and indeterminate PALF.
TPE improved NLS and OS in a propensity-matched cohort of patients with PALF. Patients receiving TPE had lower INR and bilirubin levels and higher MAP on day 4.
本研究旨在评估治疗性血浆置换(TPE)在儿科急性肝衰竭(PALF)中的安全性和疗效。
所有年龄在 2-18 岁之间患有 PALF 的儿童均纳入本研究。干预组包括接受完整三次 TPE 治疗的 PALF 患者子集,而匹配对照组则通过倾向评分匹配从未接受任何 TPE 治疗的患者队列中得出。倾向评分匹配基于国际标准化比值(INR)、肝性脑病(HE)程度、年龄、胆红素和血氨水平进行。主要结局指标是两组患者在第 28 天的原生肝存活率(NLS)。
在总共 403 例 PALF 患者中,有 65 例接受 TPE 的患者和 65 例匹配的对照组患者纳入分析。两组患者的基线参数具有可比性。在第 4 天,TPE 组患者的 INR(P=0.001)、胆红素(P=0.008)明显更低,平均动脉压(MAP)(P=0.033)更高。TPE 组的 NLS 为 46.15%,对照组为 26.15%。TPE 组的总生存率(OS)为 50.8%,对照组为 35.4%。Kaplan-Meier 生存分析显示,接受 TPE 治疗的患者 NLS 明显高于对照组(P=0.001)。亚组分析显示,TPE 治疗的 NLS 获益主要见于甲型肝炎相关和原因不明的 PALF。
在经过倾向评分匹配的 PALF 患者队列中,TPE 提高了 NLS 和 OS。接受 TPE 的患者在第 4 天的 INR 和胆红素水平更低,MAP 更高。